Demographics and Clinical Characteristics of 42 Patients at Initial Presentation Before First 223Ra Dose
| Characteristic | n | % | Range |
| 223Ra doses (n = 201) | |||
| Completed | 19 | 45.2 | |
| In progress | 1 | 2.4 | |
| Stopped | 22 | 52.4 | |
| Gleason score | |||
| 10–8 | 27 | 64.3 | |
| 7–6 | 14 | 33.3 | |
| NA | 6 | 14.3 | |
| Tumor stage | |||
| T4 | 0 | 0 | |
| T3 | 23 | 54.7 | |
| T2 | 4 | 9.6 | |
| NA | 15 | 35.7 | |
| Clinical stage | |||
| IV | 16 | 38.1 | |
| III | 20 | 47.6 | |
| IIB | 4 | 9.5 | |
| NA | 2 | 4.8 | |
| Eastern Cooperative Oncology Group performance status | |||
| 0 | 10 | 24.4 | |
| 1 | 15 | 36.6 | |
| 2 | 12 | 29.3 | |
| 3 | 4 | 9.8 | |
| 4 | 0 | 0.0 | |
| World Health Organization pain scale | |||
| 0 | 13 | 31.7 | |
| 1 | 7 | 17.1 | |
| 2 | 16 | 39.0 | |
| 3 | 5 | 12.2 | |
| 4 | 0 | 0.0 | |
| Additional data | |||
| Age (y) | 71.7 | 43–88 | |
| Time of last chemotherapy cycle (wk) (n = 22) | 6.5 | 0.9–53.9 | |
| Time of last EBRT (wk) (n = 6) | 5.5 | 0.9–53.9 | |
| PSA (μg/L) | 54.0 | 1.0–1,778.0 | |
| ALP (U/L) | 137 | 48.0–913.0 | |
| Hemoglobin (g/dL) | 11.0 | 6.6–15.1 | |
| Platelets (K/uL) | 187 | 114–413 | |
| Absolute neutrophil (K/uL) | 4.51 | 1.5–21.4 |
NA = Data not available; EBRT = external-beam radiation therapy.